How Cipla Is Shaping Lung Leadership Beyond Asthma, AMR Plans
CEO Vohra Talks Strategy With Scrip
Executive Summary
CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.
You may also be interested in...
Cipla Founding Family Pares Stake
Founding Hamied family trims holding in Cipla but the third generation currently at the helm operationally underscores that the promoter group remains invested in the front-line firm’s future.
Cipla Founding Family Pares Stake But Third Generation Affirms Continuity
Founding Hamied family trims holding in Cipla but the third generation currently at the helm operationally underscores that the promoter group remains invested in the front-line firm’s future.
Lupin’s Foncoo Partnership Beginning Of China Challenge To AZ, Cipla?
Lupin’s partnership with Shenzhen Foncoo marks the Indian firm's much-awaited entry into China. Will this and more planned alliances make Lupin a worthy respiratory challenger to AstraZeneca, compatriot Cipla and others in a country where chronic respiratory diseases are the second leading cause of death?